Universitat Autònoma de Barcelona
2017
Altres ajuts: MSC/RD12-0042-0020
Altres ajuts: MSC/RD12/0042/0013
Epilepsy has been associated with cardiovascular comorbidity. This study aimed to assess the potential association between cardiovascular risk factors (s), antiepileptic drugs (s), and etiology. A single-center retrospective epilepsy cohort from the decade of 2004-2013 was assessed. Poisson regression models with robust variance were estimated to obtain prevalence ratios () according to prescription and etiology. After excluding patients in the monotherapy group with vascular etiology or previous cardiovascular events, in the remaining 400 patients, enzyme-inducer s (s), especially phenytoin (), were associated with higher prevalence of dyslipidemia (a 1.77, p < .05), compared to valproic acid. No etiology was associated with higher prevalence of any . Patients treated with s, especially , had higher prevalence of dyslipidemia.
Article
English
Antiepileptic drugs; Cardiovascular risk factors; Comorbidity; Epilepsy
Ministerio de Economía y Competitividad CM13/00051
Brain and behavior ; Vol. 7, issue 2 (Feb. 2017)
open access
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
https://creativecommons.org/licenses/by/4.0/
